Detalles de la búsqueda
1.
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Liver Int
; 44(6): 1456-1463, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38488749
2.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Hepatol Res
; 53(2): 172-178, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36214071
3.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res
; 52(3): 235-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861090
4.
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.
J Infect Chemother
; 28(9): 1231-1234, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35534339
5.
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis.
Hepatol Res
; 51(12): 1219-1228, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34534398
6.
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma.
Hepatol Res
; 51(6): 694-701, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687130
7.
Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.
Hepatol Res
; 50(5): 557-564, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883211
8.
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
J Gastroenterol Hepatol
; 35(8): 1420-1425, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31950525
9.
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
J Gastroenterol Hepatol
; 35(5): 855-861, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31609495
10.
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.
J Viral Hepat
; 26(11): 1266-1275, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31278795
11.
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Liver Int
; 44(7): 1736-1737, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38717049
12.
The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
Acta Med Okayama
; 73(4): 333-339, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31439956
13.
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Acta Med Okayama
; 72(4): 401-406, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30140089
14.
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Oncology
; 93 Suppl 1: 113-119, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29258090
15.
Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
Acta Med Okayama
; 70(1): 1-12, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899604
16.
Roles of alcohol consumption in fatty liver: a longitudinal study.
J Hepatol
; 62(4): 921-7, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25433160
17.
[A case of renal salt-wasting syndrome during chemotherapy for advanced gastric cancer].
Gan To Kagaku Ryoho
; 42(2): 225-7, 2015 Feb.
Artículo
en Japonés
| MEDLINE | ID: mdl-25743144
18.
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Hepatol Int
; 17(3): 606-614, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36583842
19.
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Cancer Med
; 12(17): 17559-17568, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537956
20.
Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Cancers (Basel)
; 15(12)2023 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37370853